<DOC>
	<DOCNO>NCT02317965</DOCNO>
	<brief_summary>The purpose study detect whole chromosome abnormality maternal blood .</brief_summary>
	<brief_title>Non-Invasive Screening Fetal Aneuploidy</brief_title>
	<detailed_description>The purpose study detect whole chromosome abnormality chromosomes 13 , 16 , 18 , 21 , X Y , fetus analysis cell free compound sample DNA ( cf DNA c DNA , respectively ) maternal blood . In addition , major deletion duplication chromosome 1 , 4 , 5 , 22 detect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>â€¢ Subject pregnant woman 1854 year age 822 week ' gestation inclusive ; Subject additional risk indicator fetal chromosome aneuploidy , include one following : Maternal age &gt; 34 year estimate date delivery ; Positive serum screen test suggest fetal aneuploidy ; Previous positive noninvasive cfDNA test acceptable Fetal ultrasound abnormality suggest fetal chromosomal abnormality ; Personal family history Down syndrome chromosomal aneuploidy . Willing provide write informed consent Willing recontacted subsequently additional information and/or test necessary . Subjects enter study meet follow criterion : Fetal demise time blood draw ; Previous specimen donation protocol ; Unwilling lack capacity provide inform consent comply study procedure ; Currently treatment cancer Any history autoimmune disease Any pelvic mass Previous history radiation pelvis Any history current evidence twin demise gestational age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>